Oncternal Therapeutics Stock Probability of Future Stock Price Finishing Under 0.01
| ONCT Stock | USD 0.75 0.04 5.63% |
Oncternal |
Oncternal Therapeutics Target Price Odds to finish below 0.01
The tendency of Oncternal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.01 or more in 90 days |
| 0.75 | 90 days | 0.01 | nearly 4.88 |
Based on a normal probability distribution, the odds of Oncternal Therapeutics to drop to $ 0.01 or more in 90 days from now is nearly 4.88 (This Oncternal Therapeutics probability density function shows the probability of Oncternal Stock to fall within a particular range of prices over 90 days) . Probability of Oncternal Therapeutics price to stay between $ 0.01 and its current price of $0.75 at the end of the 90-day period is about 10.56 .
Given the investment horizon of 90 days Oncternal Therapeutics has a beta of -1.49. This indicates as returns on its benchmark rise, returns on holding Oncternal Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Oncternal Therapeutics is expected to outperform its benchmark. Additionally Oncternal Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Oncternal Therapeutics Price Density |
| Price |
Predictive Modules for Oncternal Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oncternal Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Oncternal Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Oncternal Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncternal Therapeutics is not an exception. The market had few large corrections towards the Oncternal Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oncternal Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncternal Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.82 | |
β | Beta against Dow Jones | -1.49 | |
σ | Overall volatility | 1.16 | |
Ir | Information ratio | -0.17 |
Oncternal Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncternal Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncternal Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncternal Therapeutics generated a negative expected return over the last 90 days | |
| Oncternal Therapeutics has high historical volatility and very poor performance | |
| Oncternal Therapeutics has some characteristics of a very speculative penny stock | |
| Oncternal Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oncternal Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Gold Down Over 3 Rigetti Computing Shares Spike Higher |
Oncternal Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncternal Stock often depends not only on the future outlook of the current and potential Oncternal Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncternal Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.9 M | |
| Cash And Short Term Investments | 34.3 M |
Oncternal Therapeutics Technical Analysis
Oncternal Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Oncternal Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Oncternal Therapeutics. In general, you should focus on analyzing Oncternal Stock price patterns and their correlations with different microeconomic environments and drivers.
Oncternal Therapeutics Predictive Forecast Models
Oncternal Therapeutics' time-series forecasting models is one of many Oncternal Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Oncternal Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Oncternal Therapeutics
Checking the ongoing alerts about Oncternal Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Oncternal Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Oncternal Therapeutics generated a negative expected return over the last 90 days | |
| Oncternal Therapeutics has high historical volatility and very poor performance | |
| Oncternal Therapeutics has some characteristics of a very speculative penny stock | |
| Oncternal Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oncternal Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Gold Down Over 3 Rigetti Computing Shares Spike Higher |
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.